MitrAssist

Company Overview

Snapshot

Founded in April 2009 by Gil Naor, MitrAssist operates with 1–10 employees. The company has secured funding across 5 rounds from 7 investors, with its Series C funding round occurring in July 2023.

Business overview

MitrAssist is a Health Tech & Life Sciences company focused on developing a minimally invasive treatment for mitral regurgitation (MR). The company's core technology involves a proprietary valve implant designed to be placed on top of the natural valve, working in unison to enhance functionality. This valve-in-valve approach aims to overcome challenges associated with MR, offering an alternative treatment solution for patients. MitrAssist's product, made from biomedical and biological materials, is currently in clinical trial stage and targets the global healthcare market, specifically hospitals and doctors.

Strategic signal

This capital infusion signals continued investor confidence in MitrAssist's minimally invasive mitral regurgitation treatment technology and its potential to advance through clinical trials, indicating a strong forward trajectory for the company in the medical device sector despite its current non-active status.

Company Intelligence Q&A

What is MitrAssist's primary focus?

MitrAssist is dedicated to developing a minimally invasive treatment for mitral regurgitation (MR), utilizing a proprietary valve implant that works in conjunction with the natural valve to improve functionality.

When was MitrAssist founded and by whom?

MitrAssist was founded in April 2009 by Gil Naor.

What is the current status of MitrAssist's operations?

MitrAssist is currently non-active, having ceased to operate in January 2026.